QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
ARCA:LCTX

Lineage Cell Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume963,119 shs
Market Capitalization$164.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.29 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone510 871 4188
Employees50

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.52 million
Book Value$0.74 per share

Profitability

Net Income$-11,710,000.00
Net Margins-1,326.00%

Miscellaneous

Market Cap$164.98 million
Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive LCTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LCTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Lineage Cell Therapeutics (ARCA:LCTX) Frequently Asked Questions

What stocks does MarketBeat like better than Lineage Cell Therapeutics?

Wall Street analysts have given Lineage Cell Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Lineage Cell Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Lineage Cell Therapeutics' key competitors?

Who are Lineage Cell Therapeutics' key executives?

Lineage Cell Therapeutics' management team includes the following people:
  • Mr. Brian M. Culley, CEO, Pres & Director (Age 49, Pay $772.74k)
  • Ms. Brandi L. Roberts, Chief Financial Officer (Age 46, Pay $550.01k)
  • Mr. Chase C. Leavitt, Gen. Counsel & Corp. Sec. (Age 39, Pay $321.79k)
  • Ioana C. Hone, Director of Investor Relations
  • Mr. James Knight, Sr. VP & Head of Corp. Devel.
  • Dr. François Binette M.Sc., Ph.D., Sr. VP & Global Head of R&D
  • Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D., Sr. VP of Clinical & Medical Affairs (Age 52)
  • Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 66)
  • Dr. Rami Skaliter, Chief Exec. Officer of Cell Cure Neurosciences Ltd. (Age 62)
  • Dr. Harold D. Waitz, VP of Regulatory Affairs & Quality Control (Age 78)

What is Lineage Cell Therapeutics' stock symbol?

Lineage Cell Therapeutics trades on the ARCA under the ticker symbol "LCTX."

How do I buy shares of Lineage Cell Therapeutics?

Shares of LCTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is Lineage Cell Therapeutics?

Lineage Cell Therapeutics has a market capitalization of $0.00 and generates $3.52 million in revenue each year. The company earns $-11,710,000.00 in net income (profit) each year or $0.14 on an earnings per share basis. Lineage Cell Therapeutics employs 50 workers across the globe.

What is Lineage Cell Therapeutics' official website?

The official website for Lineage Cell Therapeutics is www.lineagecell.com.

How can I contact Lineage Cell Therapeutics?

Lineage Cell Therapeutics' mailing address is 2173 SALK AVENUE SUITE 200, CARLSBAD CA, 92008. The company can be reached via phone at 510 871 4188 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.